Strand Life Sciences, a subsidiary of India’s Reliance Industries Limited and a leading genomics and bioinformatics company, announced the launch of a novel blood-based test for early detection of multiple cancers.
Called CancerSpot, the test uses the latest globally accepted methylation profiling technology to identify cancer tumour DNA fragments, the company said.
“CancerSpot works off a simple blood sample and uses a proprietary genome sequencing and analysis process to identify DNA methylation signatures of cancer in the blood,” it said.
Reliance subsidiary launches pioneering cancer test
The company said CancerSpot’s signatures, derived from Indian cohorts, have been shown to be robust and applicable across global ethnicities.
Isha Ambani Piramal, Member of the Board, Reliance Industries Limited, said Strand’s novel cancer early detection test exemplifies the company’s vision of delivering transformative healthcare solutions.
“We are committed to utilising the power of genomics in advancing healthcare and wellness, and improving lives in India, as well as the rest of the world,” she said.
Speaking at the grand opening of Strand’s new state-of-the-art Genomics Diagnostics & Research Centre in Bengaluru, Dr. Ramesh Hariharan, CEO and Co-Founder, Strand Life Sciences, said early warning is the key to battle cancer ─ and win it.
“We are proud to launch an accessible early cancer detection test that will enable people to stay ahead of cancer,” he said.
Hariharan said the new Genomics Diagnostics & Research Centre will drive the CancerSpot programme and accelerate efforts to develop new solutions, support research efforts, and deliver novel life-saving diagnostics for both Indian and global populations.
Follow us on
